Some environmental carcinogens may be responsible for a modest increase in the numbers of cancers after years of exposure. Economic or political factors weigh against widespread bans of carcinogens. However, lists of chemicals and agents that cause cancer assume that everyone is equally susceptible to their carcinogenic effects.
For example, it can be predicted that BRCA1 or BRCA2 mutation carriers should be highly susceptible to the carcinogen formaldehyde. High formaldehyde levels can overwhelm normal enzyme detoxification systems or detoxification genes may be inadequate or missing. Formaldehyde that is not detoxified causes strands of DNA to cross-link to each other and to nearby proteins. Carriers of mutations in BRCA1/2 dependent pathways are deficient in the ability to undo these cross-links.
Human myeloid leukemias are linked to formaldehyde. Inherited biallelic BRCA2 gene defects and other defects in BRCA1/2 mediated pathways dramatically increase risks for myeloid leukemia, even among infants. In 12 of 15 studies, heterozygous BRCA1 or BRCA2 mutations increase risks for myeloid leukemias. Moreover, chromosome arms lost in hereditary breast cancers encode enzymes essential for formaldehyde metabolism. BRCA1/2 mutation carriers may reduce their very high cancer risks by lowering their exposure to formaldehyde.
Cancers associated with many other hereditary gene deficits can also be stimulated by distinct environmental hazards. Widespread education could prevent or delay some cancers in mutation carriers. 
Background
Formaldehyde is a direct human mutagen and known carcinogen [1] [2] [3] [4] . Yet widespread human exposures occur during manufacture and use of resins, particle board, plywood, leather goods, paper, pharmaceuticals, cosmetics, baby products, and food. Latex paint, fingernail cosmetics, tobacco smoking, varnishes, floor finishes, auto exhaust and organic combustion all release formaldehyde. Nearly 5 million tons of formaldehyde were produced in the US in 2003, constituting 5% of gross national product [1] and representing a powerful economic force.
Minimal levels of exposure required to produce cancers and other effects on health. Potentially serious common routes of exposure to formaldehyde include inhalation, from occupational exposure and environment, dermal, from occupational handling, and intramuscular or subcutaneous from vaccines. Fig. 1 gives minimal levels of inhalation and oral ingestion associated with cancers and other adverse health effects [1] [2] [3] [4] [5] [6] . Exposures to 38 ppm may occur in the plastics industry and to 8.3 ppm in biology teaching laboratories.
Formaldehyde related cancers.
Nasopharyngeal, sinonasal cancer and myeloid leukemia [3, 5] develop at 2 -5.9 ppm formaldehyde in air (Fig. 1) . Nasal epithelium in rats contains stem cells that can produce myeloid white cells [6] . Inhaled formaldehyde might damage these nasal stem cells and cause myeloid leukemia. Individuals with nasopharyngeal cancer have elevated risks for leukemia and other hematological malignancies. Genetic susceptibility loci for nasopharyngeal cancer are all associated with leukemias. Pathogenic mechanisms in hematologic and nasopharyngeal malignancies may have some common features [7] .
Mechanisms for formaldehyde induced cancers. Formaldehyde chemically cross-links strands of DNA to each other and to nearby proteins. Carriers of mutations in BRCA1 or BRCA2 genes are deficient in the ability to repair cross-linked DNA. If cells survive without correct repairs, then DNA does not reproduce properly, further mutations become likely and DNA instructions may be misread. Chromosome breaks, gains and losses of chromosomes may result. So BRCA1/2 mutation carriers should be at especially high risk for formaldehyde related cancers.
Formaldehyde itself can exist as polymers of varying length which may form cross linkers with varying reach. The reactions of formaldehyde in DNA-protein mixtures, have been modeled by mixtures of deoxynucleosides and amino acids [8] . Cross-linked products that were chemically irreversible, stable and readily isolated were Cys-CH2-dG, Cys-CH2-dA, and Cys-CH2-dC. The amino acids Histidine and Tryptophan also formed stable cross-links although in lower yield. Three lysine cross-linked products were labile in solution, supporting widely reported reversibility of formaldehyde-induced cross-links between lysine rich histones and DNA [8] .
Formaldehyde detoxification by specialized metabolic pathways. Normal metabolism produces formaldehyde and it occurs naturally in plants, fruits, vegetables, animals and seafood. These sources are generally too low to cause permanent harm and are managed by reactions and metabolism within the digestive tract. Formaldehyde is primarily metabolized by glutathione-dependent formaldehyde dehydrogenase (ADH3) and aldehyde dehydrogenases (ALDHs) enzymes in alternative pathways (Fig.  2) . Formaldehyde is converted to formate, which is then eliminated in the urine as a sodium salt, broken down to CO 2 and water, or entered into the single-carbon pool.
Deficiencies in any of the enzymes in Fig.  2 would increase damage from reactive oxygen species because unmetabolized formaldehyde causes inflammation. Inhibition of the alcohol (ADH) or aldehyde dehydrogenases (ALDH2) in Fig. 2 has significant impact on formaldehyde toxicity [9] . ADH3 is a member of the alcohol dehydrogenase gene family expressed in many tissues. There are different frequencies of ADH3 alleles among different nationalities.
DNA cross-links, chromosome breaks and chromosome abnormalities are favored by saturating formaldehyde metabolizing pathways with environmental formaldehyde. Exogenous addition products form between formaldehyde and DNA in a highly nonlinear fashion; a 21.7-fold increase in exposure caused a 286-fold increase in exogenous adducts [10] . As shown below, overwhelming formadehyde detoxification is especially likely to cause chromosomal abnormalities in BRCA1/2 mutation carriers [11] .
Formaldehyde is more dangerous for some people. One way an inherited cancer gene mutation may target specific tissues is by increasing cancer susceptibility to environmental carcinogens [12] . This theory can be tested against risks for cancers associated with formaldehyde in BRCA1/2 mutation carriers. Repair of large DNA-protein cross-links caused by formaldehyde requires pathways containing normal BRCA1 and BRCA2 proteins (Fig. 3 , [13, 14, 12] ).
Current descriptions of an exquisite specificity for BRCA1 and BRCA2 mutations in causing breast and ovarian cancer require some unique, tissue specific property of BRCA1/2
Loss of BRCA1 mediated inhibition of estrogen receptor signaling could contribute to this specificity [15] [16] [17] ].
An analysis of cancer incidence data found that cancer targets in BRCA1/2 mutation carriers are in fact not exquisitely specific for breast and ovary. There are increased risks for cancers in several other tissues [18] . Moreover, people with compromised pathways containing BRCA1/2 and appropriate risk factors are highly prone to develop cancers mediated by some organ specific inflammatory infections. In these cases, the cancer targets are determined by the organ specific infections and not by the BRCA mutation [12, 19] . All tissues are probably unduly susceptible to carcinogens if the carcinogens can exploit the inherited deficit. All tissues have inherited premutated (cancer) stem cells.
Methods
As previously described [12, 18, 19] , the literature was systematically searched for relative risk data on second primary cancers in carriers or likely carriers of mutations in BRCA1/2 genes. Data found in appropriate studies was used directly in Table 1 without combining. No exclusions were made for percentages of mutation carriers in the population, for survival, or for loss of subjects to follow-up. merous environmental carcinogens that can exploit deficits in the pathways in Fig 3, formaldehyde is among the most abundant and best studied. Six different major and independent criteria (Tests 1-6 below) were devised and used to evaluate risks for formaldehyde associated cancers in mutation carriers (tests 1-6 in results and discussion).
Testing formaldehyde associated cancer risks in mutation carriers. Of nu-

Results and Discussion
Test 1. Mutation carriers have widely varying cancer risks. Female mutation carriers have high risks for breast /ovarian cancer as a group but individual risks within this group vary greatly. There is no single risk associated with BRCA1 or BRCA2 carrier status [20] . Defective BRCA genes increase risks for cancers in organs other than breast and ovary but individual mutation carriers again differ greatly [18] . These results implicate an increased susceptibility in organs exposed to environmental carcinogens and/or deficits in additional genes [12] . Test 2. BRCA1/2 gene mutations are associated with myeloid leukemia. Inherited mutations in BRCA1/2, Fanconi anemia and ATM genes share the ability to compromise the pathways in Fig. 3 , hindering complex repairs needed to remove DNA-protein cross-links, and to control aberrant DNA rearrangements [21] . These mutations are all associated with leukemias, especially myeloid leukemias. This association is especially strong for homozygous or biallelic mutations in BRCA2 (Fanconi protein D1). Six children with biallelic BRCA2 mutations all developed leukemia at median age 2.2 years, with 4 of 6 developing acute myeloid leukemia (AML) [22] . Biallelic BRCA2 mutation patients have a 79% cumulative probability of leukemia (primarily AML) by age 10 years ( [23] and Table 1 ). Table 1 do not support chemotherapy for breast cancer as the major cause of excess AML in mutation carriers.
Homozygous or biallelic mutations
in BRCA1 are incompatible with human life but heterozygous BRCA1 mutations are well known. Carriers of heterozygous mutations in either BRCA1 or BRCA2 have increased risks for myeloid leukemia Table 1 summarizes risks for myeloid leukemia from 15 studies (A -O) of heterozygous BRCA1/2 mutation carriers or individuals eligible for mutation testing. 12 of the 15 studies reported risks for leukemia or myeloid leukemia that are elevated by at least 50%. Risks may be even greater because none of the 15 studies included populations that had all tested positive for mutation and data was not corrected for mortality.
Test 2. Mutations in other genes
encoding the BRCA1/2 pathway (Fig. 3) are associated with myeloid leukemia and would prevent correct repair of formaldehyde damage. Other hereditary cancer related conditions are also associated with homozygous or biallelic mutations in genes encoding proteins within the model pathway (Fig. 3) . These conditions are Fanconi anemia caused by inactivation of one of 13 Fanconi anemia genes and ataxiatelangiectasia (A-T) caused by inactivation of the ATM gene.
Mutations in Fanconi anemia genes.
In Fanconi anemia patients, summary relative risks for AML were 703.3 [363.7-1354.5] [21] . This suggests that functional Fanconi proteins are essential to prevent AML [24] . Few stringent genotype-phenotype connections have emerged for Fanconi anemia. This suggests other genes and environmental factors modify the phenotype [25] .
Mutations in Fanconi genes contribute to a subset of sporadic AML [26] [27] [28] . In heterozygous carriers, lymphocytes show increased sensitivity to mutagens, but are not blocked in G2 phase as in full Fanconi Anemia [29, 30] . Heterozygous mutation in the Fanconi J gene prevents the encoded helicase from unwinding DNA [31] , suggesting one mechanism.
Other relationships exist between leukemias and the pathway in Fig 3. A characteristic fusion protein (BCR/ABL) is found in AML (and in CML) that interferes with the formation of nuclear FANCD2 foci (Fig 3) , but this interference can be reversed by the ectopic expression of BRCA1 [32] .
Mutations in the ATM gene (Fig. 3) may increase risks for myelod leukemias. In addition to requiring BRCA and Fanconi proteins, complex DNA damage (and replication fork stalling) also activate ATM (Fig. 3) . ATM modulates the loading of recombinational repair proteins onto translocation breakpoint hotspots. This protects against inappropriate recombination and translocations characteristic of myeloid leukemias [33] . The checkpoint in Fig. 3 stabilizes the genome by stopping the cell cycle so that cells with damaged DNA can complete repairs. In AML, activated ATM fails to engage this checkpoint [34] . There are isolated reports of AML associated with ATM mutation.
Test 3. Formaldehyde causes some DNA damage that requires the pathway in Fig. 3 . Many studies show mutations in BRCA1/2 dependent pathways compromise repair of DNA damage from cross-linking agents. Laboratory experiments with cells show that formaldehyde is one of these cross-linking agents. Repairing the complex DNA damage it causes requires BRCA1, BRCA2 (Fanconi protein D1), and 13 other Fanconi proteins (Fig. 3) [13] .
DNA-protein cross-links exhibit a doseresponse relationship to formaldehyde exposure in the respiratory tract of laboratory animals at exposure concentrations relevant to human exposures. In peripheral white blood cells of occupationally exposed workers, DNA-protein cross-links increased significantly vs controls and had a linear relationship with years of exposure [35] . BRCA1/2 related pathways also partici- pate in preventing formaldehyde related collateral DNA damage. This includes increased cell proliferation (which increases the probability that damaged cells will multiply and acquire further errors), bone marrow toxicity and immunosuppression (which can reactivate latent viral infections), and inflammation (which can produce cross-links due to oxidative damage).
Test 4. Pharynx associated cancers in mutation carriers.
Formaldehyde is implicated in very rare nasopharyngeal and sinonasal cancers [3, 6] . The annual incidence of nasal tumors in the United States is < 1 in 100,000 people per year. Such rare outcomes are difficult to study due to a lack of statistical power.
Nasal sinus cancer occurred among 2245 known BRCA1 carriers and 8496 untested relatives (Table 1 , study L). Two "nose cancers" were found among 471 known heterozygous BRCA2 carriers and 2186 untested family members. (Table 1 , study K) One of two buccal cavity cancers in 1160 relatives of A-T patients was nasopharyngeal cancer in a 6 year old [36] . In addition to causing cancer itself, formaldehyde might facilitate human papilloma virus (HPV) infections by damaging both the epithelial barrier and immunity. HPV infection has been implicated in oropharyngeal cancer, a site where nasal sinus cancer originates. The gene for the formaldehyde scavenger ADH3 may even be lost in HPV associated tumors [37] .
Computational models predict the nose absorbs approximately 90% of inhaled formaldehyde at resting inspiration. The exposure of oral cavity structures to formaldehyde markedly increases during heavy exercise, [38] as breathing shifts to oral. Cancers of the oral cavity are the most frequent solid tumors in Fanconi homozygotes with relative risk >200 times normal [23, 21] . For heterozygotes or potential heterozygotes (Table 1) , most studies report some increase in risks for cancers within the oral cavity.
Different incidences of cancers linked to formaldehyde in different environments.
Geographic variation in nasopharyngeal carcinoma reflects a complex etiology of several subtypes. It is not currently possible to separate environmental, viral (Epstein Barr virus), and genetic components as first or second hits. High to intermediate rates in endemic areas contrast markedly with the uniformly rare rates seen in most of the world [39] . Leukemia rates also differ substantially for different racial and ethnic groups living exposed to different levels of environmental formaldehyde. Leukemia incidence is lowest among American Indians/Alaskan natives (6.5 per 100,000).
Test 5. Comparisons of chromosome abnormalities.
Greater numbers of DNA-protein cross-links were found in breast cancer patients than in matched controls [40] and formaldehyde has been positively associated with breast cancer risk [41] . It is well known that BRCA1/2 related pathways help protect against chromosome losses. 81% of BRCA1 deficient breast tumors lose chromosome 4q [11] . Similarly 40% of BRCA1 deficient breast cancers have lost chromosome 12q [11] . These losses were much more common than in control tumors. The human alcohol dehydrogenase genes essential for formaldehyde detoxification are found in a cluster on chromosome 4q, and ALDH2 is found on chromosome 12q (Fig. 2) . Loss of either chromosome 4q or 12q destroys genes for the main protective metabolic pathways (Fig. 2) that protect against formaldehyde. Either loss then may accelerate latent and occult breast tumors.
Fanconi anemia patients with AML and myelodysplastic syndrome commonly lose one copy of chromosome 7. Formaldehyde exposure associates with chromosome 7 loss in the stem/ progenitor cells where leukemia may originate [1] .
Losses of genetic material from chromosome 5 and chromosome 7 common in myeloid leukemias are also associated with hereditary breast cancers. 86% of BRCA1 associated breast tumors lost chromosome 5q [11] and 27% of BRCA2 breast cancers lost a marker on chromosome 7 [42] . The inherited gene defects may also facilitate loss of one copy of chromosome 17, containing BRCA1 and p53 genes. In myeloid leukemias, chromosome 17 is frequently lost or involved in complex chromosomal abnormalities including balanced translocations involving the BRCA1 locus [43] . These observations suggest some pathogenic mechanisms in leukemias may be related to those in hereditary breast cancers.
Test 6. Treatment related risk factors for myeloid leukemia. In the studies in Table 1 , most of the excess risk for AML is probably not due to therapy for breast cancer. AML occurs with virtual certainty in children and infants with biallelic mutations in BRCA2. AML also occurs at very young ages in Fanconi anemia patients, before any chemotherapy or radiation has been given. Moreover defects in pathways requiring normal BRCA gene function are associated with other hematopoietic malignancies that are not generally considered to be therapy related [21] .
The first chemotherapy regimen for breast cancer was not published until 1975 with large trial results appearing in 1976 [44] . The first three studies in Table 1 include patients diagnosed with breast cancer before adjuvant chemotherapy became widely used. In comparison to later studies, the three pre-chemotherapy studies in Table 1 do not show less risk for AML. In one early study, women over 55 had no excess risk for any second cancer while women younger than 55 still had over 3 times the risk for myeloid leukemia [ A few of the more recent studies in Table   1 show no excess risk for myeloid leukemia, consistent with environmental or additional genetic variation. Relative risks for myeloid leukema if platinum chemotherapy was likely to be used are not substantially higher (Table 1 , studies E and F). Moreover both studies E and F reported elevated risks for cancers of the pharynx region, perhaps related to inhalation or facilitated HPV infection.
Radiation therapy. Therapeutic doses of targeted field radiation causes very little or no increased risk of myeloid cancers. This is consistent with myeloid stem cells being more radiation resistant than non-stem cells [45, 46] .
Despite younger ages, breast cancer patients with BRCAI/2 mutations present at a similar stage, display a normal acute reaction to radiotherapy and have a similar prognosis compared to sporadic breast cancer patients [47] . An increased risk of radiation therapy related-AML is largely confined to young women with stage III breast cancer, (spread to lymphoid tissue). These patients are more likely to receive radiation in some combination with cytotoxic chemotherapy. In stage 1 disease, radiation is given alone and there is very little excess risk for AML [48] . Nonetheless sound arguments remain to limit radiation exposure in mutation carriers.
Other inherited cancer associated conditions and environmental carcinogens. Table 2 gives additional examples of inherited cancer associated conditions that have increased susceptibility to environmental carcinogens. Common findings are increased sensitivity to cancer associated infections, to radiation, and to chemical carcinogens. This shows that the phenomenon of increased sensitivity to the environmental carcinogen formaldehyde is probably representative of a broad general phenomenon. Further studies of the relationship between genetic inheritance and environmental cancer susceptibility are needed. Sites of bone infarcts, metallic prostheses and prior internal fixation. Ionizing radiation, intravenous radium and Thorotrast. Alkylating agents may also contribute, apparently independent of radiotherapy [15] .
Clinical Significance
CNS hemangioblastomas; renal cell carcinomas; pheochromocytomas; pancreatic islet cell tumors; endolymphatic sac tumors.
VHL / HIF1 Von Hippel−Lindau syndrome
High-level exposure to trichloroethylene and reactive metabolites are genotoxic to kidney proximal tubule. This is a tumor-initiating process linked with mutational changes in the VHL tumor suppressor gene [16] Wilms' kidney WT1 /p53 Familial Wilms tumor Hair coloring products, vaginal infections, tea drinking, prenatal pesticides.
Breast, sarcoma, adrenal, brain.
TP53 (p53)/ p53
Li-Fraumeni syndrome Virtually all DNA tumor viruses that cause tumors in experimental animals or humans encode proteins that inactivate both Rb and p53 [17] Eye RB1 /RB Hereditary retinoblastoma Virtually all DNA tumor viruses that cause tumors in experimental animals or humans encode proteins that inactivate both Rb and p53 [17] Footnotes to Table 2 
